Related Experiment Video
Updated: May 2, 2026
05:16
Sleeve Gastrectomy in Mice using Surgical Clips
Published on: November 14, 2020
7.5K
Semaglutide Hype or Hope: Evidence-based Review in Diabesity
Sunil Gupta1, Brij Mohan Makkar2, Jothydev Kesavadev3
1Managing Director, Department of Diabetology, Nagpur, Maharashtra, India, Corresponding Author.
The Journal of the Association of Physicians of India
|March 12, 2026
Summary
Ozempic (semaglutide) offers significant benefits for managing type 2 diabetes and obesity in India. This review examines its global efficacy, safety, and practical use for "diabesity" management.
Area of Science:
- Endocrinology and Metabolism
- Pharmacology
- Public Health
Background:
- India faces a dual epidemic of diabetes and obesity, ranking second and third globally.
- A need exists for comprehensive treatments for
- diabesity
- despite advancements in glycemic control and weight management therapies.
Purpose of the Study:
- To review global clinical data on semaglutide (Ozempic) for
- diabesity
- management.
- To discuss the practical application of Ozempic in the Indian context.
Main Methods:
- Review of global clinical trial data for semaglutide.
- Analysis of real-world usage and safety profiles.
- Consideration of the Indian healthcare landscape.
Main Results:
- Semaglutide (Ozempic) demonstrates efficacy in glycemic control and significant weight loss.
- Additional benefits include cardiovascular protection, renal benefits, and improved peripheral arterial disease function.
- Gastrointestinal side effects are the most common adverse events, consistent with GLP-1 receptor agonists.
Conclusions:
- Ozempic is approved in India for type 2 diabetes mellitus (T2DM) as a first-line adjunct therapy.
- Extensive global and Indian data support semaglutide's efficacy and safety profile.
- The drug presents a valuable option for managing
- diabesity
- in India, with established benefits and manageable side effects.
More Related Videos
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
993
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
993
01:19Type I Diabetes III: Clinical Manifestations
26
Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the...
26
01:26Type II Diabetes I: Introduction
17
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
17
01:25Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
17
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated...
17
01:26Hypoglycemia
30
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
30
01:28Diabetic Nephropathy
32
Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration...
32